Prognostic Significance of LPCAT1 in Adult Acute Myeloid Leukemia Patients with FAB Subtype M2.
10.19746/j.cnki.issn.1009-2137.2023.01.010
- Author:
Yu LIU
1
;
Ya-Jun LIU
2
;
Lu YANG
1
;
Yu ZHANG
1
;
Dan-Feng ZHANG
1
;
Zhong-Xing JIANG
1
;
Chong WANG
1
;
Yan-Fang LIU
3
;
Shu-Juan WANG
4
Author Information
1. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
2. Department of Orthopaedics, Brown University, Warren Alpert Medical School/Rhode Island Hospital, Rhode Island, the United States, Providence, RI 02903.
3. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.E-mail: fccliuyf1@zzu.edu.cn.
4. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.E-mail: fccwangsj1@zzu.edu.cn.
- Publication Type:Journal Article
- Keywords:
FAB subtype M2;
LPCAT1;
acute myeloid leukemia;
prognosis
- MeSH:
Humans;
Adult;
Prognosis;
Leukemia, Myeloid, Acute/metabolism*;
Survival Analysis;
Proportional Hazards Models;
Risk Factors;
1-Acylglycerophosphocholine O-Acyltransferase
- From:
Journal of Experimental Hematology
2023;31(1):64-70
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the prognostic value of LPCAT1 in acute myeloid leukemia (AML).
METHODS:TaqMan-based reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect relative expression of LPCAT1 in 214 newly diagnosed adult AML patients and 24 normal controls. Survival functions were estimated using the Kaplan-Meier method and were compared by the Log-rank test. A Cox proportional hazard regression model was used to identify prognostic factors.
RESULTS:The expression level of LPCAT1 in adult AML was 34.37%(1.83%-392.63%), which was significantly lower than 92.81%(2.60%-325.84%) of normal controls (P<0.001). The prognostic significance of LPCAT1 was evaluated in 171 non-acute promyelocytic leukemia patients with complete clinical information and prognostic data. Survival analysis showed that the expression level of LPCAT1 had no significant effect on the prognosis of the whole cohort. However, in AML patients with FAB subtype M2 (AML-M2), the 2-year relapse-free survival (RFS) rate of patients with low LPCAT1 expression was 35.4%(95%CI: 0.107-0.601), which was significantly lower than 79.2%(95%CI: 0.627-0.957) of patients with high LPCAT1 expression (P=0.012). Multivariate analysis showed that low expression of LPCAT1 was an independent risk factor for RFS of AML-M2 patients (HR=0.355, 95%CI: 0.126-0.966, P=0.049).
CONCLUSION:In adult AML patients LPCAT1 shows low expression. Low LPCAT1 expression is an independent risk factor for RFS in M2-AML patients.
